BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vogler J, Böttger R, Al Fayez N, Zhang W, Qin Z, Hohenwarter L, Chao PH, Rouhollahi E, Bilal N, Chen N, Lee B, Chen C, Wilkinson B, Kieffer TJ, Kulkarni JA, Cullis PR, Witzigmann D, Li SD. Altering the intra-liver distribution of phospholipid-free small unilamellar vesicles using temperature-dependent size-tunability. J Control Release 2021;333:151-61. [PMID: 33771624 DOI: 10.1016/j.jconrel.2021.03.025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Al Fayez N, Böttger R, Brown J, Rouhollahi E, Li S. The mechanism of Hepatocyte-Targeting and safety profile of Phospholipid-Free small unilamellar vesicles. International Journal of Pharmaceutics 2022;628:122269. [DOI: 10.1016/j.ijpharm.2022.122269] [Reference Citation Analysis]
2 Al Fayez N, Rouhollahi E, Ong CY, Wu J, Nguyen A, Böttger R, Cullis PR, Witzigmann D, Li SD. Hepatocyte-targeted delivery of imiquimod reduces hepatitis B virus surface antigen. J Control Release 2022;350:630-41. [PMID: 36058352 DOI: 10.1016/j.jconrel.2022.08.058] [Reference Citation Analysis]
3 Böttger R, Chao PH, Al Fayez N, Pauli G, Nguyen A, Hohenwarter L, Bilal N, Mohammed GK, Knappe D, Hoffmann R, Li SD. Simultaneous Chromatographic Quantitation of Drug Substance and Excipients in Nanoformulations Using a Combination of Evaporative Light Scattering and Absorbance Detectors. Mol Pharm 2022. [PMID: 35506592 DOI: 10.1021/acs.molpharmaceut.2c00021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Liu Y, Yang G, Hui Y, Ranaweera S, Zhao CX. Microfluidic Nanoparticles for Drug Delivery. Small 2022;:e2106580. [PMID: 35396770 DOI: 10.1002/smll.202106580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Al Fayez N, Böttger R, Rouhollahi E, Cullis PR, Witzigmann D, Li SD. Improved Liver Delivery of Primaquine by Phospholipid-Free Small Unilamellar Vesicles with Reduced Hemolytic Toxicity. Mol Pharm 2021. [PMID: 34546758 DOI: 10.1021/acs.molpharmaceut.1c00520] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]